Based on clinical trials, mTOR inhibition in combination with an endocrine therapy is a new therapeutic strategy for women with advanced breast cancer who have previously relapsed on a non-steroidal aromatase inhibitor (49). Here, CYP19A1 is linked to breast carcinoma.